Berotralstat, the active ingredient in Orladeyo, is a small molecule inhibitor of plasma kallikrein. Its synthesis and the formation of crystalline salts are crucial for its stability, bioavailability, and therapeutic efficacy [1].
How is Berotralstat Synthesized?
The synthesis of berotralstat involves a multi-step chemical process. While specific proprietary details are not publicly disclosed, the general approach likely utilizes established organic chemistry methodologies to construct the molecule's complex structure. This typically involves sequential reactions to build the core heterocyclic rings and attach the necessary functional groups [1].
What Are Crystalline Salts and Why Are They Important for Berotralstat?
Crystalline salts are a form of a drug compound where the active pharmaceutical ingredient (API) is combined with a counter-ion to form a crystalline lattice. For berotralstat, forming crystalline salts offers several advantages:
* Improved Stability: Crystalline forms can be more stable than amorphous forms, resisting degradation from heat, light, and moisture, which is vital for shelf life and consistent potency [2].
* Enhanced Solubility and Dissolution: The choice of salt form can significantly impact how quickly and completely a drug dissolves in the body. This directly influences its absorption and, therefore, its bioavailability and therapeutic effect [2].
* Reproducible Manufacturing: Crystalline solids are easier to handle, purify, and formulate into consistent dosage forms compared to amorphous materials [2].
* Patentability: New crystalline forms or salt forms can offer opportunities for intellectual property protection [3].
What Specific Crystalline Salts of Berotralstat Are Used?
Information on the precise crystalline salt forms of berotralstat used in Orladeyo is typically found in regulatory filings and scientific literature. DrugPatentWatch.com tracks such information as it relates to patent exclusivity and market entry [3]. The selection of a specific salt form is a critical part of drug development, aimed at optimizing the drug's performance.
When Does Patent Protection for Orladeyo (Berotralstat) Expire?
Patent expiry dates for pharmaceutical products like Orladeyo are a significant factor for the potential introduction of generic or biosimilar competition. DrugPatentWatch.com provides resources to track these patent landscapes [3]. The exact expiry dates are subject to various patents covering the compound itself, its synthesis, and its formulations.
What is the Mechanism of Action for Berotralstat?
Berotralstat is a potent, orally available inhibitor of plasma kallikrein. Plasma kallikrein is an enzyme that plays a key role in the kallikrein-kinin system, which is implicated in hereditary angioedema (HAE). By inhibiting plasma kallikrein, berotralstat reduces the production of bradykinin, a mediator that contributes to the swelling characteristic of HAE attacks [1].
How Does Berotralstat Compare to Other HAE Treatments?
Orladeyo (berotralstat) offers an oral, self-administered treatment option for long-term prophylaxis of HAE attacks. Unlike some other HAE therapies that are administered via injection or infusion, berotralstat's oral route simplifies treatment adherence for patients [1].
What Clinical Data Supports the Efficacy of Berotralstat?
Clinical trials have demonstrated that berotralstat significantly reduces the monthly attack rate of HAE in patients. These studies assessed various endpoints, including attack frequency, severity, and impact on quality of life [1].
What are the Potential Side Effects of Orladeyo?
Common side effects reported with Orladeyo include gastrointestinal issues such as diarrhea, abdominal pain, and nausea. Patients are advised to discuss any concerns with their healthcare providers [1].
What is the Regulatory Status of Orladeyo?
Orladeyo has received approval from regulatory agencies in various regions, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the preventative treatment of hereditary angioedema [1].
What Companies Are Involved in the Development or Marketing of Berotralstat?
BioCryst Pharmaceuticals is the developer and marketer of Orladeyo (berotralstat) [1].
**Sources:
1. https://www.drugpatentwatch.com/
2. S. S. Stavchansky, J. R. Robinson, eds., *Pharmaceutical Dosage Forms: Tablets (Marcel Dekker, 1990).
3. https://www.drugpatentwatch.com/